Combination Therapy with Flutamide and Castration (Orchiectomy or LH-RH Agonist) in Untreated Patients with Advanced Prostate Cancer

  • A. Dupont
  • F. Labrie
  • L. Cusan
  • J. L. Gomez
  • M. Tremblay
  • Y. Lacourcière
  • J. Emond
  • G. Monfette
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 124)


Since the observations reported by Huggins and his colleagues (1941), the standard treatment of advanced prostate cancer has been a choice between orchiectomy and estrogens (Huggins and Hodges 1941; Nesbit and Baum 1950; Jordan et al. 1977; Mettlin et al. 1982; Murphy et al. 1983). Following such neutralization of testicular androgens, a positive response is observed in 60%–80% of patients for a limited time interval, thus leaving 20%–40% of patients in progression without any effect of treatment. Moreover, in the 60%–80% of patients who initially respond, relapse of the disease is usually seen within 6-24 months (Resnick and Grayhack 1975) and 50% of them are expected to die within the next 5 months (Johnson et al. 1977; Slack and Murphy 1984).


Advanced Prostate Cancer Adrenal Androgen Bilateral Adrenalectomy Prostate Cancer Tissue Testicular Androgen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams JB (1985) Control of secretion and the function of C19-delta-5-steroids of the human adrenal gland. Molec cell Endocr 45:1–17CrossRefGoogle Scholar
  2. Aseelin J, Mélançon R, Moachon G, Bélanger A (1980) Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)an-thracene-induced mammary tumors and their hormonal control. Cancer Res 40:1612–1622Google Scholar
  3. Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1988) Total androgen blockade versus castration in metastatic cancer of the prostate. In: Motta M, Serio M (eds), Hormonal Therapy of Prostatic Diseases: Basic and Clincal Aspects, Medicom, Bussum pp 302–311Google Scholar
  4. Bélanger A, Dupont A, Labrie F (1984) Inhibition of basai and adrenocorticotropin-stimu-lated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J Clin Endocrinol Metab 59:422–426PubMedCrossRefGoogle Scholar
  5. Bélanger A, Brochu M, Cliche J (1986) Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 62:812–815PubMedCrossRefGoogle Scholar
  6. Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L, Monfette G (1989) Comparison of residual C-19 steroids in plasm and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgen in men. J Steroid Biochem 32:695–698PubMedCrossRefGoogle Scholar
  7. Bhanalaph T, Varkarakis MJ, Murphy GP (1974) Current status of bilateral adrenalectomy of advanced prostatic cancer. J Clin Endocrinol Metab 59:422–426Google Scholar
  8. Brendler H (1969) Current cancer concepts: therapy with orchiectomy or estrogens or both. JAMA 210:1074–1075PubMedCrossRefGoogle Scholar
  9. Brendler H, Prout GR Jr (1962) A cooperative group study of prostatic cancer. Stilbestrol versus placebo in advanced progressive disease. Cancer Chemother Rep 16:323–327PubMedGoogle Scholar
  10. Brisset JM, Bertagna C, Fiet K, de Gery A, Hucher M, Husson JM, Tremblay D, Raynaud JP (1987) Total androgen blockade versus orchiectomy in stage D prostate cancer. In: Klijn JGM (ed) Hormonal Manipulation of Cancer: Pep tides Growth Factors and New (anti)steroidal agents, vol 18, Raven Press, New York, pp 17–30Google Scholar
  11. Brochu M, Bélanger A (1987) Increase in plasma steroid glucuronide levels in men from infancy to adulthood. J Cell Endocr Metab 64:1283–1287CrossRefGoogle Scholar
  12. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Door FA, Blumenstein DA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without Flutamide in prostatic carcinoma. New Engl J Med 321:419–424PubMedCrossRefGoogle Scholar
  13. Cutler GB Jr, Glenn M, Bush M, Hodgen GD, Graham CE, Loriaux DL (1978) Adrenarche: a survey of rodents, domestic animals and primates. Endocrinology 103:2112–2118PubMedCrossRefGoogle Scholar
  14. de Peretti E, de Forest MG (1978) Pattern of plasma dehydroepiandrosterone sulfate levels in human from birth to adulthood. Evidence for testicular production. J Cell Endocr Metab 47:572–577CrossRefGoogle Scholar
  15. Drago JR, Santen RJ, Lipton A, Worgul TJ, Harvey HA, Boucher A, Manni A, Rohner TJ (1984) Clinical effect of aminoglutethimide, medical adrenalectomy in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447–1450PubMedCrossRefGoogle Scholar
  16. Ferguson JD (1975) Limits and indication for adrenalectomy and hypophysectomy in the treatment of prostatic cancer. In: Bracci U, Di Silverio F (eds) Hormonal Therapy of Prostatic Cancer, Cofese Edizioni, Palermo, pp 201–207Google Scholar
  17. Geller J, Albert J, Nachtseim DA, Loza DC (1988) Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 15:53–61PubMedGoogle Scholar
  18. Harper ME, Pike A, Peeling WB, Griffiths K (1974) Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocr 60:117–125PubMedCrossRefGoogle Scholar
  19. Harrison JH, Thorn GW, Jenkins D (1953) Total adrenalectomy for reactivated carcinoma of the prostate. N Engl J Med 248:86–92PubMedCrossRefGoogle Scholar
  20. Huggins C, Hodges CV (1941) Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297Google Scholar
  21. Huggins C, Scott WW (1945) Bilateral adrenalectomy in prostatic cancer. Ann Surg 122:1031CrossRefGoogle Scholar
  22. Johnson DE, Scott WW, Gibbons RP, Prout GR, Schmidt JD, Chu JTM, Gaeta J, Sarott J, Murphy GP (1977) National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report. Cancer Treat Rep 61:317–323PubMedGoogle Scholar
  23. Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. S Afr Med J 70:1411–1413Google Scholar
  24. Kahan A, Delrieu F, Amor B, Chiche R, Steg A (1984) Disease flare induced by D-Trp6-GnRH analogue in patients with metastatic prostatic cancer. Lancet 1:971–972PubMedCrossRefGoogle Scholar
  25. Labrie C, Bélanger A, Labrie F (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123:1412–1417PubMedCrossRefGoogle Scholar
  26. Labrie F, Veilleux R (1986) A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8:293–300PubMedCrossRefGoogle Scholar
  27. Labrie F, Dupont A, Bélanger A, Lacourcière Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4:579–594PubMedCrossRefGoogle Scholar
  28. Labrie F, Dupont A, Bélanger A, Emond J, Monfette G (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Nat Acad Sci U.S.A. 81:3861–3863CrossRefGoogle Scholar
  29. Labrie F, Dupont A, Bélanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology, Lippincott, Philadelphia, pp 193–217Google Scholar
  30. Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7:67–74PubMedCrossRefGoogle Scholar
  31. Labrie F, Dupont A, Bélanger A, Lachance R (1987 a) Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. J Urol 138:804–806PubMedGoogle Scholar
  32. Labrie F, Luthy L, Veilleux R, Simard J, Bélanger A, Dupont A (1987 b) New concepts on the androgen sensitivity of prostate cancer. In Murphy G (ed) Proc 2nd Int Symp on Prostate Cancer, Alan Liss, New York, pp 145–72Google Scholar
  33. Labrie F, Bélanger A, Veilleux R, Lacoste D, Labrie C, Marchetti B, Poulin R, Dupont A, Cusan L, Luthy I (1988 a) Rationale for maximal androgen withdrawal in the therapy of prostate cancer. Baillière’s Clin Oncol 2:597–619Google Scholar
  34. Labrie F, Dupont A, Giguère M, Cusan L, Bergeron N, Emond J, Monfette G, Lacourcière Y, Boucher H, Lachance R (1988 b) Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur J Cancer Clin Oncol 12:1869–1878CrossRefGoogle Scholar
  35. Labrie F, Dupont A, Cusan L, Gomez JL, Emond J, Monfette G (1990) Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J Steroid Biochem 37:943–950CrossRefGoogle Scholar
  36. Labrie F (1991) Treatment of prostate cancer. In: Strauss III, JF (ed) Endocrinology and Metabolism Clinics of North America, W. B. Saunders, in pressGoogle Scholar
  37. Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286CrossRefGoogle Scholar
  38. MacFarlane DA, Thomas LP, Harrison JH (1960) A survey of total adrenalectomy in cancer of the prostate. Am J Surg 99:562–572PubMedCrossRefGoogle Scholar
  39. Maddy JA, Winternitz WW, Norrell H (1971) Cryohypophysectomy in the management of advanced prostatic cancer. Cancer 28:322–328PubMedCrossRefGoogle Scholar
  40. Medical Letter (1991) Drugs of choice for cancer chemotherapy. The Medical Letter on Drugs and Therapeutics 33 (issue 840, March 22)Google Scholar
  41. Mettlin C, Natarajan N, Murphy GP (1982) Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 5:277–321PubMedGoogle Scholar
  42. Moghissi E, Alban F, Horton R (1984) Origin of plasma androstanediol glucuronide in men. J Clin Endocrinol Metab 59:417–421PubMedCrossRefGoogle Scholar
  43. Morales PA, Brendler H, Hotchkiss RS (1955) The role of the adrenal cortex in prostatic cancer. J Urol 73:399–409PubMedGoogle Scholar
  44. Murphy GP, Beckley S, Brady MF, Chu M, DeKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening S, McKieri CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway M (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264–1272PubMedCrossRefGoogle Scholar
  45. Murray R, Pitt P (1985) Treatment of advanced prostatic cancer resistant to conventional therapy with aminoglutethimide. Eur J Cancer Clin Oncol 21:453–458PubMedCrossRefGoogle Scholar
  46. Namer M, Amiel J, Toubol J (1988) Anandron (RU23908) associated with orchiectomy in stage D prostate cancer: preliminary results of a randomized double-blind study. Am J Clin Oncol 11 (Suppl 2):S191–S196PubMedCrossRefGoogle Scholar
  47. Narayana AS, Loening SA, Culp DA (1981) Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 52:152–153CrossRefGoogle Scholar
  48. Navratil H (1987) Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Progress Clin Biol Res 243A: 401–410Google Scholar
  49. Neri R, Florance K, Koziol P, Van Cleave S (1972) A biological profile of a non-steroidal antiandrogen, SCH13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 91:427–437PubMedCrossRefGoogle Scholar
  50. Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143:1317–1320CrossRefGoogle Scholar
  51. Ponder BAJ; Shearer RJ, Pocock RD, Miller J, Easton D, Chilvers CED, Dowsett M, Jeffcoate SL (1984) Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer 50:757–763PubMedCrossRefGoogle Scholar
  52. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42:283–288PubMedCrossRefGoogle Scholar
  53. Raynaud JP (1988) Antiandrogens in combination with LHRH agonist in prostate cancer. Am J Clin Oncol 11 (Suppl 2):S132–S147PubMedCrossRefGoogle Scholar
  54. Resnick MI, Grayhack JT (1975) Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2:141–161PubMedGoogle Scholar
  55. Robinson MRG, Shearer RJ, Fergusson JD (1974) Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 46:555–559PubMedCrossRefGoogle Scholar
  56. Sanford EJ, Paulson DF, Rohner TJ, Drago JR, Santen RJ, Bardin CW (1977) The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 118:1019–1021PubMedGoogle Scholar
  57. Simard J, Luthy I, Guay J, Bélanger A, Labrie F (1986) Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 8:293–300Google Scholar
  58. Slack NH, Murphy GD (1984) NPCP Participants: criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 11:337–342PubMedGoogle Scholar
  59. Smith JA, Glode LM, Wettlaufer JN, Strein BS, Glass AG, Max DT, Anbar D, Jagst CL, Murphy G (1985) Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of the prostate. Urology 20:106–114CrossRefGoogle Scholar
  60. Sogani PC, Ray B, Whitmore WF Jr (1975) Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology 6:164–166PubMedCrossRefGoogle Scholar
  61. Stoliar B, Albert DJ (1974) SCH 1352 in the treatment of advanced carcinoma of the rostate. J Urol 111:803–807PubMedGoogle Scholar
  62. Warner B, Worgul TJ, Drago J, Demers L, Dufau M, Max D, Santen RJ, Abbott Study Group (1973) Effect of very high doses of D-leucine-6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest 71:1842–1855CrossRefGoogle Scholar
  63. Waxman JH, Was JAH, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Olivier RTD (1983) Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. Brit Med J 286:1309–1312CrossRefGoogle Scholar
  64. Worgul TJ, Santen RJ, Samojlik E, Veldhuis JD, Lipton A, Harvey HA, Drago JR, Rohner TJ (1983) Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol 129:51–55PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. Dupont
    • 1
  • F. Labrie
    • 1
  • L. Cusan
    • 1
  • J. L. Gomez
    • 1
  • M. Tremblay
    • 1
  • Y. Lacourcière
    • 1
  • J. Emond
    • 1
  • G. Monfette
    • 1
  1. 1.Medical Research Council Group in Molecular EndocrinologyCHUL Research Center and Laval UniversityQuebecCanada

Personalised recommendations